<DOC>
	<DOCNO>NCT00257686</DOCNO>
	<brief_summary>The purpose study compare efficacy safety pitavastatin pravastatin elderly patient</brief_summary>
	<brief_title>Study Compare Efficacy Safety Pitavastatin Pravastatin Elderly Patients</brief_title>
	<detailed_description>Following wash-out dietary lead-in period , patient receive either Preavastatin Pitavastatin 12 week , order establish efficacy pitavastatin reduce cholesterol level .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Males postmenopausal female ( age 65 year older Eligible , able participate , give informed consent Must follow restrictive diet Diagnosis primary hypercholesterolemia combine dyslipidemia Serum CK must less equal 1.5 x ULRR 2 3 permit evaluation Week 4 1 Agree available Exclusion Criteria Homozygous familial hypercholesterolemia Conditions may cause secondary dyslipidemia Uncontrolled diabetes mellitus ( HbA1c &gt; 8 % ) . Any condition might significantly alter absorption , distribution , metabolism , excretion drug . History pancreatic injury pancreatitis , impaired pancreatic function/injury Liver injury Impaired renal function Current obstruction urinary tract difficulty void due mechanical well inflammatory condition , likely require intervention course study regard clinically meaningful Serum CK &gt; 5 x ULRR without clinical explanation Uncontrolled hypothyroidism define TSH &gt; ULRR Any severe acute illness severe trauma last 3 month prior Visit 1 Major surgery , 3 month prior Visit 1 Significant CVD prior randomization Evidence symptomatic heart failure , gross cardiac enlargement ; significant heart block cardiac arrhythmia . History uncontrolled complex ventricular arrhythmia , uncontrolled atrial fibrillation/flutter uncontrolled supraventricular tachycardia ventricular response rate &gt; 100 beat per minute rest . Left ventricular ejection fraction &lt; 0.25 ; History symptomatic cerebrovascular disease Any condition discretion investigator Known HIV infection Poorly control uncontrolled hypertension Prior current know muscular neuromuscular disease type ; Neoplastic disease Drug abuse continuous consumption 65 mL pure alcohol per day Exposure investigational new drug within 30 day study entry ingestion drug know toxic major organ system Current recent use supplement know alter lipid metabolism History hypersensitivity HMGCoA reductase inhibitor ; Concomitant medication permit Resistant lipidlowering medication . Known hypersensitivity intolerance lipid lower agent Excessive obesity Any factor make regular clinic attendance morning impractical Signs mental dysfunction factor likely limit ability cooperate study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Kowa</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>combine</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>elderly</keyword>
	<keyword>pitavastatin</keyword>
	<keyword>NK-104</keyword>
</DOC>